The development of STING agonists for cancer has been beset by safety issues and discontinued programmes, but Daiichi Sankyo is hoping a new antibody-drug conjugate (ADC) could succeed where others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback